Medically reviewed by Dr. Ben Soffer, DO

Dr. Ben Soffer is a board-certified physician licensed in Florida and New Jersey. He personally reviews every intake and treats every Discreet Ketamine patient, so the comparison below reflects real clinical practice rather than a call-center script.

At-Home Ketamine vs. IV Infusion Clinics: What Patients Need to Know

Ketamine has one of the strongest evidence bases in modern psychiatry for depression that has not responded to standard antidepressants. The first controlled trial showing a rapid antidepressant effect was published in 2000 (Berman et al.), and a landmark 2006 randomized trial confirmed that a single dose produced meaningful improvement in treatment-resistant major depression within hours (Zarate et al.). Later multi-site trials reproduced the result (Murrough et al., 2013), and a 2022 meta-analysis of 79 real-world studies found the effect holds up outside the research setting (Alnefeesi et al.).

Today that same medicine reaches patients in two ways. At-home sublingual ketamine is physician-prescribed troches or rapidly dissolving tablets taken at home during a structured session with remote telehealth supervision. Infusion-clinic ketamine is delivered intravenously or intramuscularly in a medical facility under direct staff supervision. Both are used for the same conditions: treatment-resistant depression, anxiety, PTSD, and certain chronic pain syndromes. Both work, and neither is universally better.

Who qualifies? Broadly, medically stable adults who have tried at least one conventional treatment and been screened for the cardiovascular, psychiatric, and substance-use risks that make unsupervised dosing unsafe. Someone in an acute suicidal crisis, or with uncontrolled heart disease, is usually not a candidate for the at-home route.

Cost is where the two settings diverge most. A standard six-session IV induction typically runs $2,400 to $4,800 out of pocket, because insurers rarely cover off-label ketamine. A comparable four-to-eight-week at-home induction runs roughly $300 to $650 including clinical care and medication. Spravato (intranasal esketamine) is the one FDA-approved option with a realistic insurance path (FDA). The sections below compare the two settings honestly on safety, efficacy, cost, and logistics, then cover who fits each.

Safety: Where Each Setting Wins

The clinic model has real advantages that come from putting trained staff and emergency equipment in the same room as you. A nurse or physician is right there if your blood pressure spikes, you get nauseous, or you have a wave of acute anxiety, and any of those can be treated within seconds. Continuous monitoring runs for the whole session: automated BP cuff, pulse oximetry, sometimes cardiac monitoring. Defibrillator, airway tools, IV fluids, and rescue medications are on hand. For patients with significant medical complexity (cardiovascular disease, recent MI, uncontrolled hypertension), that level of in-the-room capability is the safer fit.

The at-home model wins on a different axis. Many patients have their best sessions at home precisely because they aren't in a medical setting; the familiarity of your own bedroom reduces baseline anxiety in a way that meaningfully changes the experience. Sublingual ketamine is also absorbed more slowly than IV, so the risk of an acute adverse reaction is proportionally lower. And legitimate at-home programs screen out high-risk patients before prescribing, in line with the American Psychiatric Association consensus on ketamine screening, dosing, and monitoring (Sanacora et al., 2017). That screening is itself a safety mechanism. The safest at-home program is one that says no to the wrong candidates, and a good intake process is your first safety net.

Much of the at-home safety story is really about supervision that continues between sessions, which is exactly what patients tend to notice.

"Have to give Dr. Ben Soffer an A+. He's a very caring individual who is focused on me and my well being as a patient when we meet via the internet. Very professional and good with communicating about how I'm doing, side effects if they should occur. He wants me to be careful and not fall, and cares about a positive benefit for me."

Jack Webb, verified Discreet Ketamine patient (Google review)

Efficacy: What the Data Shows

Real-world response rates between the two settings are roughly comparable. IV clinic-based protocols see 65 to 75 percent response in treatment-resistant depression (Murrough et al., 2013). Sublingual at-home protocols see 60 to 70 percent in comparable populations. IV has higher bioavailability (approximately 100% versus 20-30% sublingual), but effective dosing compensates. Time to meaningful response is similar (24 to 72 hours for both) (Wilkinson et al., 2018), and the duration of effect between sessions is comparable (roughly one to two weeks).

The biggest efficacy variable in at-home treatment isn't the route of administration. It's set and setting: the psychological preparation you bring to each session. In the clinic, the setting is standardized and the staff guides you. At home, that responsibility falls more on you and your provider's protocols. We have a longer piece on this at the integration process.

That slower, self-directed arc is what long-term patients describe when the work actually lands.

"Ketamine is helping me confront and address previously buried and inaccessible layers of deep pain and rage and sadness in a safe environment over time. Dr. Ben's expertise and own personal experience has been an invaluable resource on my ongoing journey to live with less suffering."

Moshe, verified Discreet Ketamine patient (Google review)

Cost

For patients paying out of pocket, which is most of them, at-home runs roughly four to six times less expensive over a typical treatment course. For the reference price table (IV $400-800/session, Spravato $600-900, at-home $300-400/mo all-in) plus the granular per-provider comparison including induction phase, maintenance, and total annual cost, see ketamine therapy cost comparison for 2026.

Convenience and Logistics

A clinic visit requires travel each way (often thirty to sixty minutes), two to three hours on-site, a driver for the trip home afterward, scheduling that fits the clinic's hours, and time off work. An at-home session requires a quiet, private 60-to-90-minute block, a trusted person available (not necessarily in the room), a light stomach beforehand (a light meal 2–3 hours before), and no driving for the rest of the day.

For patients with full-time jobs, childcare responsibilities, chronic pain that makes travel difficult, or anyone in a rural area without a nearby clinic, the at-home option is often the only realistic one.

Who Should Choose Clinic

A clinic setting is the better fit if you have uncontrolled hypertension (above roughly 160/100), a recent cardiac event or significant cardiovascular disease, a history of severe adverse reactions to anesthesia, an active suicidal crisis that needs rapid and intensive intervention, no reliable support person at home, or very high body weight requiring higher doses that benefit from IV precision.

Who Should Choose At-Home

At-home is a good fit if you have a stable medical history (well-controlled hypertension is fine), a reliable support person available during sessions, a quiet and private space for treatment, geographic or financial barriers to clinic access, a preference for being in your own environment, and the willingness to do the prep work that makes home sessions work.

If you've already decided at-home is the right setting, the next question is which program to use. The market has consolidated to a handful of national telehealth providers with meaningfully different models (psychiatrist-led vs. nurse-practitioner-led, fixed protocols vs. flexible dosing, with-or-without integration coaching). Two pieces that go deeper on this: Mindbloom vs. Joyous, which compares the two leading session-based programs side by side, and the best at-home ketamine programs of 2026, which surveys the broader field.

What the Decision Really Comes Down To

Most patients pursuing ketamine therapy aren't in a clinical emergency. They're dealing with chronic depression, anxiety, PTSD, or pain that has resisted other treatments. For that population, the relevant question isn't which setting is "safer" in the abstract; both are safe when done right. The relevant question is which setting they'll actually stick with for long enough to see results. A clinic course that gets abandoned after two sessions because the patient can't afford it or can't get the time off is less effective than a twelve-week at-home course they finish. What keeps people in treatment is usually the felt sense of being looked after.

"Very helpful and efficient. Feel supported in my experience."

Jane Seales, verified Discreet Ketamine patient (Google review)

Frequently Asked Questions

Is at-home ketamine as effective as IV infusion clinics?

For most patients, yes. Real-world response rates are comparable: 60-70% in sublingual at-home programs vs. 65-75% in IV clinic protocols, both for treatment-resistant depression. IV has higher bioavailability (~100% vs. ~25-30% sublingual), but at-home dosing is adjusted upward to compensate. Time to response (24-72 hours) and duration of effect between sessions are similar. The biggest efficacy variable isn't the route; it's set, setting, and integration work.

How much cheaper is at-home ketamine than clinic IV?

Roughly 4-6x cheaper per treatment course. A standard 6-session IV induction at a clinic runs $2,400-$4,800 out-of-pocket. The same 4-8 week induction period at an at-home program like Discreet Ketamine runs $300-$650 (clinical care + medication, 1-3 month plan). Ongoing maintenance follows the same ratio: clinic visits at $400-$800 each vs. at-home monthly plans starting at $250.

When should you choose IV ketamine over at-home?

Clinic-based IV is the better fit for: uncontrolled hypertension (above ~160/100), recent cardiac events or significant cardiovascular disease, history of severe adverse reactions to anesthesia, an active suicidal crisis needing rapid intensive intervention, no reliable support person at home, or very high body weight requiring IV-precision dosing. For maintenance treatment in stable patients, at-home is generally the better fit.

Is IV ketamine safer than at-home sublingual?

In specific senses, yes: a clinic has trained staff, continuous monitoring (BP cuff, pulse oximetry), and emergency equipment in the same room. But at-home programs build safety in differently: rigorous intake screening that excludes high-risk candidates, slower sublingual absorption (lower acute reaction risk), and remote physician availability. For appropriately screened patients, both settings are safe; the comparison is about what failure modes each setting handles best.

Does insurance cover IV ketamine for depression?

Almost never. IV ketamine is prescribed off-label for psychiatric conditions, and insurers don't cover off-label compounded ketamine. Spravato (intranasal esketamine) is the one ketamine modality with FDA approval and a realistic path to insurance coverage, though even that requires prior authorization and copays often run $150-$300/session. Most patients pay out-of-pocket for both clinic IV and at-home sublingual.

What's the time commitment difference?

A clinic visit is 30-60 minutes of travel each way, 2-3 hours on-site (prep, infusion, recovery), often a driver for the trip home, scheduling within clinic hours, and time off work. An at-home session is a 60-90 minute private block, a light stomach (a light meal 2–3 hours before), no driving for the rest of the day, and a peer supervisor reachable nearby. For full-time workers and parents, the at-home logistics are typically the only realistic option.

Can you switch from IV ketamine to at-home sublingual?

Yes; it's a common pathway. Patients who begin with IV for acute stabilization (severe TRD with suicidal ideation) often transition to sublingual maintenance once they're past crisis. The clean handoff works when both providers communicate. The pharmacokinetics differ enough that prior IV experience doesn't always predict sublingual tolerability, so most prescribers start the at-home dose at the standard new-patient level.

What's the response rate difference between clinic and at-home ketamine?

In published real-world data, IV clinic-based protocols see 65-75% response in treatment-resistant depression. Sublingual at-home protocols see 60-70% in comparable populations. The gap is small enough to be within population variance, and the larger variable is whether the patient stays in treatment long enough to see results, which is where at-home's lower cost and convenience often produce the better real-world outcome.

Ready to See Which Setting Fits You?

At Discreet Ketamine, I only take on patients who are genuinely appropriate for at-home treatment, and I refer out the ones who aren't. I review every intake personally before any prescription is issued. Available to residents of Florida and New Jersey. For a related patient-perspective piece on the same decision, see why I chose at-home ketamine over clinic visits.

If cost is your main question, the full at-home ketamine cost breakdown lays out plan tiers, what each tier includes, and HSA/FSA eligibility on one canonical pricing page.

The five-minute eligibility check will give you a quick answer on whether at-home is the right fit, or whether a clinic referral makes more sense for your case.

References

1. Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 2000. PubMed The first placebo-controlled trial demonstrating ketamine's rapid antidepressant effect. Establishes the historical evidence base cited in the introduction.

2. Zarate CA, et al. A randomized trial of an NMDA antagonist in treatment-resistant major depression. Archives of General Psychiatry, 2006. PubMed Landmark RCT showing a single ketamine dose produced improvement within hours in treatment-resistant major depression. Basis for the rapid-response framing.

3. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142. PubMed: 23982301 · Free full text Foundational two-site RCT in TRD. Response rate at 24 hours: 64% with ketamine vs 28% with midazolam (OR 2.18). The basis for the "65-75% IV response rate" claim in the body.

4. Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405. PubMed: 28249076 APA-task-force consensus on screening, dosing, monitoring, and setting standards for clinical ketamine use. Underpins the "rigorous intake screening" and dosing-equivalence claims comparing IV and sublingual modalities.

5. Daly EJ, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry, 2018. PubMed Pivotal esketamine trial supporting the intranasal (Spravato) pathway discussed in the cost and insurance sections.

6. Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018;175(2):150-158. PubMed: 28969441 Establishes the 24-72 hour time-to-response window referenced throughout the post for both modalities.

7. U.S. FDA. Spravato (esketamine) prescribing information and approval. FDA The FDA approval underlying the statement that esketamine is the one ketamine modality with a realistic insurance path.

8. Alnefeesi Y, Chen-Li D, Krane E, et al. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review and meta-analysis. J Psychiatr Res. 2022;151:693-709. PubMed: 35688035 Meta-analysis of 79 real-world studies (2,665 patients) confirming substantial effectiveness across both racemic ketamine and esketamine. Establishes the real-world basis for response/remission claims.